Data With TTFields Raise Questions Around the Future of Immunotherapy in Metastatic NSCLC
August 7th 2023Tony S.K. Mok, MD, BMSc, FRCPC, FASCO, provides perspective on the use of tumor treating fields in lung cancer, the use of anti–PD-L1 inhibitors approved in China, and the potential impact of the microbiome on response with immunotherapy.
Read More
Pirtobrutinib Demonstrates Durable Efficacy in Pretreated Mantle Cell Lymphoma
August 6th 2023Nirav Shah, MD, discusses the efficacy of pirtobrutinib in patients with mantle cell lymphoma who were previously treated with a covalent BTK inhibitor and progressed, and outlines the next steps for exploration of the noncovalent BTK inhibitor in this population.
Read More
CD22-Targeted CAR T Cells Elicit Responses With Acceptable Safety in Heavily Pretreated LBCL
August 3rd 2023Matthew Frank, MD, PhD, discusses the rationale for evaluating CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma, important safety and efficacy data with this approach, next steps for this research, and how continued efforts may shed needed light on sequencing in this space.
Read More
Finding Fulfillment in Research and Patient Care
August 3rd 2023Stephen T Magill, MD, PhD, details his inspirations behind entering not just the neuro-oncology and surgical treatment field, but also the arena of meningioma care and research; provides topline advice for current fellows looking to enter this field; and details current and ongoing research in this space taking place at Northwestern Medicine.
Read More
Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC
August 1st 2023Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.
Read More
Rusfertide Improves Efficacy Vs Placebo in Phlebotomy-Dependent Polycythemia Vera
July 31st 2023Marina Kremyanskaya, MD, PhD, details the outcomes of the phase 2 trial, expands on the potential implications for rusfertide in the treatment of patients with PV, and detailed the next steps for investigating the agent in this patient population.
Read More
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
Read More
Social Determinants of Health Correlate With Lower CRC Screening Rates
July 26th 2023Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening, expands on how these social determinants of health could affect a patient’s likelihood of adhering to screening guidelines, and highlights ways to potentially address these barriers to screening.
Read More
Rini Expands on Key Clinical Trial Updates in GU Cancers from the 2023 ASCO Annual Meeting
July 20th 2023Brian I. Rini, MD, FASCO, highlights key clinical trial updates from the genitourinary cancers landscape presented at the 2023 ASCO Annual Meeting, details the implications of the CONTACT-03 data, expands on the long-term data from the phase 3 KEYNOTE-426 trial in clear cell RCC, discusses findings from the phase 3 TALAPRO-2 trial in patients with metastatic castration-resistant prostate cancer, and more.
Read More
Nausheen Ahmed, MD, explains the rationale for examining real-world outcomes observed with the use of brexu-cel in the treatment of patients with relapsed/refractory mantle cell lymphoma, details the key efficacy and safety findings from the overall population and different subgroups, and discusses what will be gained with longer follow-up of the study.
Read More
Although adjuvant treatment with ibandronate plus capecitabine resulted in a numerical improvement in overall survival vs ibandronate alone in elderly patients with moderate or high-risk early breast cancer, this did not reach statistical significance, according to long-term data from the phase 3 ICE study.
Read More
Disitamab Vedotin Plus Toripalimab Elicits Responses, Safety in Metastatic Urothelial Carcinoma
July 4th 2023The combination of disitamab vedotin with toripalimab generated responses and displayed a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma, irrespective of HER2 expression.
Read More
Ropeginterferon Alfa-2b Produces Responses, Safety in Prefibrotic Primary Myelofibrosis
June 30th 2023Harry Gill, MD, discusses the rationale for exploring ropeginterferon alfa-2b as a potential treatment option for patients early myelofibrosis and expands on the efficacy and safety data observed in the phase 2 study.
Read More
Quizartinib Plus Chemotherapy Improves EFS, RFS in Newly Diagnosed FLT3-ITD–Negative AML
June 27th 2023Pau Montesinos, MD, PhD, discusses the preliminary results of the QUIWI trial, expands on the potential implications for the use of quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD–negative acute myeloid leukemia, and details the next steps for this study and future research.
Read More
Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC
June 27th 2023Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.
Read More
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation
June 23rd 2023The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.
Read More
Obe-Cel Demonstrates Durable, Safe Responses in Relapsed/Refractory B-ALL
June 18th 2023Claire Roddie, MD, discusses the rationale for investigating obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, details the key topline findings from the FELIX trial, and provides insights on unmet needs that remain for this patient population.
Read More
First-line treatment with toripalimab in combination with gemcitabine and cisplatin resulted in a statistically significant and clinically meaningful improvement in overall survival and progression-free survival vs placebo plus chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma.
Read More
One-stage Synovectomy Does Not Lead to Worse Outcomes in D-TGCT of the Knee
June 14th 2023R. Lor Randall, MD, FACS, discusses the standard treatment approach for patients with diffuse-type tenosynovial giant cell tumor, the results of the retrospective cohort study evaluating 1- vs 2-stage synovectomies in these patients, and the importance of having additional treatment options for this patient population.
Read More
Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL
June 12th 2023Luke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with 17p deletions and TP53 mutations, and the investigation of liso-cel in patients with relapsed/refractory CLL.
Read More